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httpcense.Abstract Background: Pulmonary tuberculosis (TB) is a widely spread disease, usually treated by
multidrug therapy, nevertheless there are increasing number of cases in which medical treatment
fails and requires surgical intervention specially those with large cavitary lesions or persistent spu-
tum positive for Ziehl Neelsen (ZN) stain. Our objective was to assess the role of pulmonary resec-
tion in treating certain cases of pulmonary TB and its outcome and morbidity.
Methods: In this study 45 tuberculous patients were selected for pulmonary resection (patients
with large cavitary lesions and persistent sputum positive for ZN stain, massive hemoptysis,
relapsed TB and treatment failure patients). Twenty-eight lobectomies (18 lobectomy for patients
with relapsed TB with large cavities, persistent sputum positive and 10 lobectomy for patients with
massive hemoptysis). Fourteen elective pneumonectomy for patients with symptomatic destroyed
lung and 3 completion pneumonectomy were carried out.
Results: Thirty-ﬁve patients (78%) were sputum positive preoperatively and 31 patients (69%)
had cavitary lesions radiologically, MDR-TB was found retrospectively in 16 patients. Mortality
was 4.4%, and postoperative complications were encountered in 44.4% of the participants.
Forty-three patients (95.5%) became sputum negative 3–9 months after surgery. Male sex, HCV
infection, operation time, and intraoperative bleeding were predictive of bad outcome in this study.
Conclusions: Surgery is effective when medical therapy fails to control pulmonary TB and its
complications. MDR-TB patients are among those who beneﬁt from pulmonary resection. Postop-
erative medical therapy is important to improve results and in achieving negative sputum
conversion in TB patients including MDR-TB patients.
ª 2013 The Egyptian Society of Chest Diseases and Tuberculosis. Production and hosting by Elsevier
B.V. Open access under CC BY-NC-ND license.322441.
com (A. Metwally).
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Although often treated with chemotherapy, tuberculosis (TB)
usually responds to the surgical solution where medical treat-
ment fails [1]. In western countries, the incidence of TB as well
as its complications requiring usually surgical treatment such
as; chronic TB empyema, destroyed lung, rather than TBis. Production and hosting by Elsevier B.V.
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386 A. Rifaat et al.related hemoptysis is much lower than in the developing coun-
tries [2] that witness losers of anti-tuberculosis chemotherapeu-
tic protocols, non adherents to treatment and increased
number of multidrug resistant TB (MDR-TB) [3].
MDR-TB, a condition deﬁned as resistance at least to both
isoniazid and rifampcin requires usually the surgical option.
Certain conditions can precipitate the development of MDR-
TB including; incomplete anti-TB treatment and intravenous
drug abuses [4].
Proper selection of patients and decision for surgical
interference can provide a high success rate and salvage of
the lung parenchyma, where medical treatment fails to control
pulmonary TB [5,6].
This prospective study was done to assess the role of
pulmonary resection in treating certain cases of pulmonary
TB, and to assess its outcome and morbidity.Patients and methods
The study was carried out at Cardiothoracic and Chest
Departments, Zagazig University Hospitals and Chest Hospi-
tal in the period between May 2009 and June 2012. Surgical
resection was carried out for 45 diagnosed tuberculous patients
who were referred to our tertiary center.
The study included 45 TB patients with; destroyed lung (14
patients), treatment failure (8 patients), relapsed pulmonary
TB (13 patients) and 10 old TB patients presented by massive
hemoptysis. The studied patients were diagnosed as pulmonary
TB by medical history, clinical examination, radiological and
laboratory investigations including sputum and broncho-alve-
olar lavage (BAL) ﬂuid ZN stain, according to ﬁle records of
the patients. Upon readmission sputum samples were collected
for sputum ZN stain and culture, positive samples were sent
for sensitivity to the ministry of health (MOHP) central
laboratories.
Surgical indications are:
1. Symptomatic destroyed lung in 14 patients (recurrent pneu-
monia and recurrent hemoptysis),
2. Massive hemoptysis in 10 patients,
3. Relapsed TB in 13 patients,
4. Treatment failure in 8 patients.
Massive hemoptysis was deﬁned as coughing of
>600 ml blood/day [9]. Multidrug resistant TB (MDR-TB)
was deﬁned as resistance at least to both isoniazid and rifamp-
cin [10]. All patients were on anti-TB therapy for a mean dura-
tion of 28 ± 6 months preoperatively.
All participants had routine pulmonary scanning with serial
chest roentgenography (CXR) and computed tomography
(CT). It was assured that all elective patients (The 35 patients
rather than the 10 patients with massive hemoptysis) had ade-
quate pulmonary reserve before the decision for resection was
undertaken.
In the 10 patients with massive hemoptysis, rigid bronchos-
copy was performed prior to surgery in order to clear tracheo-
bronchial tree and to localize and conﬁrm the side of bleeding
and double-lumen endotracheal tubes were employed in those
patients to prevent aspiration to the other lung, single-lumen
tubes were used in the rest of cases.The 28 lobectomies and 17 pneumonectomies (14 elective,
one intraoperative and 2 postoperative completion pneumo-
nectomy) were performed all through posterolateral thoracot-
omies under general anesthesia. Bronchial stumps were closed
with conventional sutures; however intercostal muscle ﬂaps
were decided intraoperative for weak stumps in 2 cases includ-
ing the completion pneumonectomy.
All patients were subjected once more to bronchoscopy
through their endotracheal tube before extubation for bron-
chial toilet. After discharge, non MDR-TB patients were sent
to chest hospital to complete their medical treatment to im-
prove the outcome of surgery, patients were submitted to
anti-TB therapy with isoniazid (5 mg/kg/day), rifampicin
(10 mg/kg/day), pyrazinamide (40 mg/kg) and ethambutol
(25 ml/kg/day) till sputum conversion. MDR-TB patients were
referred to a specialized center for individualized second line
chemotherapy according to chest hospital protocol.
Follow-up was done for all non MDR-TB participants
through monthly visits to our outpatient clinic for a mean
period of 21.4 ± 6 months (range = 15–27 months), chest
roentgenograms were done every month and sputum cultures
every 3 months. Data were collected and continuous variables
were expressed as mean ± SD, while categorical variables
were expressed as number (No.) and frequencies as (%).
Results
Table 1 showed that the study comprised 45 pulmonary tuber-
culous patients, 29 males and 16 females (with age range of 24–
68 years) who underwent pulmonary resections with mean
operative time of 163.08 ± 35.12 min. In the present study
16 patients were proved to have MDR-TB where their sensitiv-
ity reports were obtained after they underwent their surgical
procedure. Nineteen patients (42.2%) of this study were
HCV positive including the 16 MDR-TB patients, condition
of high incidence in Egyptian population, and no other co
morbidities were found.
Cavitary lung lesions were found in 31 (69%) patients
including the MDR-TB group, 29 patients (64.4%) had right
lung lesions. It was striking that 16 MDR-TB patients in this
study were HCV positive, a ﬁnding that could suggest a prob-
able correlation between HCV and response to anti-TB ther-
apy specially with the presence of history of regular anti-TB
therapy in 13 (81.25%) of those patients.
Table 2 showed that mortality due to respiratory failure
(RF) took place early postoperatively in 2 patients (4.4%);
both were HCV positive, male participants with relatively pro-
longed operative time. One of them was 64 year old patient
who underwent left pneumonectomy for destroyed lung;
whereas the second was 31 year old, smear positive MDR-
TB with intraoperative bleeding.
Apart from intra and post operative bleeding which oc-
curred in 15 patients (33.3%), postoperative complications
were encountered in 5 patients (11.1%), 2 lobectomy patients
developed empyema (>350 ml/day) with bronchopleural ﬁs-
tula (BPF) within the ﬁrst week after surgery and both under-
went completion pneumonectomy plus reinforces of their
bronchial stumps with intercostal muscle ﬂaps. In the later post
operative period, 3 pneumonectomy patients developed empy-
ema with BPF and were submitted to tailoring thoracoplasty
and transported intercostal muscle ﬂaps to close their stumps.
Table 1 Demographic and clinical proﬁle of the studied patients.
Age in years (range) 24-68
Gender (Male/Female) 9/16
Smear +ve before surgery, no. (%) 35 patients (78%)
Treatment duration before surgery (M±SD) 28 ± 6 months
Radiographic characteristic
Cavitary lesions, no.(%) 31 patients (69%)
Side, no. (%) Rt. (64.4%)/Lt. (31.2%)/Bil. (4.4%)
MDR-TB, no. (%) 16 patients (35.5%)
HCV+ve, no. (%) 19 patients 42.2%
Number of drugs used before surgery, no. (%) 4 drugs (57.8%)/5 drugs (42.2%)




Completion pneumonectomy 3 6.6
Lobectomy 28 62.2
Post-operative complications
Postoperative hemorrhage 15 33.3
Bronchopleural ﬁstula with empyema 5 11.1
Postoperative early death 2 4.4
Smear –ve after surgery 43 95.5
Post operative LOS 16.7 ± 3.62 days
Follow-up (months) 21.4 ± 6 months
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The remaining participants spent an otherwise uneventful
postoperative period, and all patients including morbidity
cases were discharged in a mean period of 16.7 ± 3.62 days
after resection (range = 8–39 days).
It was transpired that resections were very successful for the
16 MDR-TB patients in our study and all MDR-TB patients
had negative conversions within 3–9 months after operation
and till the end of the study as well as most of other
participants.
Discussion
TB is the world’s second cause of infectious disease deaths after
HIV [7]. Surgery plays a decisive role in the overall manage-
ment of MDR-TB and provides a somewhat better mortality
and morbidity. Surgical resection is done because the bacterial
count within the cavity is high and antibiotic treatment fails to
reach the site of infection. Thus, to cure the disease completely,
it is imperative to resect the cavitary lesion and damaged lung
tissue, leaving no grossly diseased lung behind [8].
Pulmonary TB and its chronic sequelae are more prevalent
in developing countries [9] where compliance to anti-TB ther-
apy is poor and the low socioeconomic status can lead to irreg-
ular treatment, a fact which was noticed in 8 patients (18%) of
the participants of the current study and they were proved to
have MDR-TB later on by culture and sensitivity among the
16 MDR-TB.
In the present study all the 16 MDR-TB patients were
chronic HCV positive. The ﬁnding looks accidental and cannot
be related to a causal relationship. This ﬁnding could beexplained by the patient fear about the hepatic complications
of the anti-tuberculous drugs which drive them to stop the
drugs without consultation, or stop the regimen prematurely
before completion of the regimen and consequently the devel-
opment of MDR-TB and failure on the next regimen.
On the other hand, all mortality and postoperative compli-
cations developed in HCV positive participants, although they
were well compensated both clinically and laboratory, but
most of those patients had low normal serum albumin (3–
3.5 mg/dl) which might let such patients susceptible to postop-
erative complications that need good nutritional status for
healing e.g., bronchopleural ﬁstula which necessitates rein-
forcement with intercostal muscle ﬂap.
It was reported that; MDR-TB is more prevalent among
retreatment cases than initial treatment cases [9,10] and reserve
drugs are generally less effective and more toxic than standard
therapy, besides they must be given daily and some need to be
taken several times a day [11,12]. Furthermore, it was reported
that 40% of non responding MDR-TB patients have calami-
tous outcome [13,14]. In the present study the 16 MDR-TB pa-
tients had received 3–5 courses of anti TB, none of these
MDR-TB patients showed improvement of their pulmonary
pathology.
In the present study, mortality was reported to be 4.4% (2
patients) both were HCV positive, male participants with pro-
longed operative time. The ﬁrst was 64 year old patient who
underwent left pneumonectomy for destroyed lung in which
massive intraoperative bleeding occurred due to dense adhe-
sions, whereas the second was 31 year old, smear positive
MDR-TB who also died due to intraoperative bleeding.
In other retrospective studies [8], early mortality was re-
ported to be less than 3%. Another study reported 7.6% mor-
tality because of the death of one patient who had a vital
capacity of less than 50% and a low FEVı, which necessitated
a pneumonectomy, resulting from laceration of the main pul-
monary artery during the hilar dissection. Such higher mortal-
ity in that study is due to the small number of patients included
in the study (one death out of all 13 patients) [15].
The occurrence of mortality in 2 patients with HCV in the
present study could not be attributed to the liver disease that
could make the patients more susceptible to major intraopera-
tive bleeding because other HCV patients had undergone a
successful surgical maneuver and uneventful post operative
time.
Sadik et al. [15] reported 92.3% cure rate (12/13 excluding
the one patient who died) in their study, which was compara-
ble to the present study where we reported a cure rate of
388 A. Rifaat et al.(95.5%) where 43 out of 45 patients showed sputum conver-
sion 3–9 months after surgery. Concurrently with Takeda
et al. [6], male gender was found to be correlated with all mor-
tality cases and with 80% of morbidity cases in our patients,
and so were certain operative factors as prolonged operative
time and intraoperative bleeding.
Pulmonary resection is usually technically difﬁcult in TB
patients, as the chronic inﬂammatory process may produce
more adhesions, chronic sepsis, scarring, and excessive bleed-
ing together with poor general condition of patient [16]. Fortu-
nately, we did not face postoperative complications listed in
previous works e.g., persistent air leak, atelectasis, organized
hemothorax or wound infection [1,6], and morbidity in our
work conﬁned itself to empyema with BPF in 11% of cases
which is lower than percentages found in other researches [15].
In order to ward off delayed operative treatment for pul-
monary TB, we coordinated with main chest hospitals in our
regions, arranged for regular meetings to address surgical pul-
monary TB candidates either with MDR-TB or destroyed
lungs to be transferred to thoracic surgery. Moreover, we held
regular seminars in their places to draw the attention of the
chest physicians to the beneﬁts of surgery for such patients.
This collaboration will drive the physicians and encourage
them to schedule more TB patients for surgery.
We maintained all the series on strict anti-TB therapy post-
operatively for at least 1 year including individualized chemo-
therapy according to cultures from resected lungs of MDR-TB
patients in a quest to reach the best of outcomes.
Conclusion
Surgery is effective when medical therapy alone fails to control
pulmonary TB and its complications. MDR-TB patients are
among those who beneﬁt from pulmonary resection. Postoper-
ative medical therapy is important to improve results and in
achieving negative sputum conversion in TB patients including
MDR-TB patients. Cooperation between physicians and sur-
geons is mandatory for proper selection of surgical candidates
and proper time for surgery.
Recommendations
Future studies are recommended for comparing tuberculosis
pathology in HCV positive and negative patients, and the rela-
tion between HCV and compliance to anti-TB drugs.
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